Effect of Medication Intake on Dental Implant‐Related Outcomes—A Scoping Review
By Alberto Monje, Maria Costanza Soldini, Emilio Couso‐Queiruga, Álvaro Babiano, Vivianne Chappuis
Originally at onlinelibrary.wiley.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Practice owners and implant surgeons now have evidence that patient medication lists should be systematically reviewed before implant placement, because several drug classes measurably alter osseointegration success, complication rates, and long-term implant survival.
Key points
- Scoping review analyzed 24 studies covering bisphosphonates, SSRIs, PPIs, anticoagulants, corticosteroids, and metformin; each drug class showed statistically significant associations with implant outcomes.
- Antiresorptive agents and SSRIs were linked to higher early implant failure rates (RR 1.8–2.6), whereas metformin use correlated with improved bone-to-implant contact in diabetic patients.
- No universal wash-out protocol exists; authors recommend individualized risk stratification using current drug lists rather than blanket contraindications.
- Findings apply to both surgical planning (pre-op medication review) and post-op maintenance (monitoring for peri-implant bone loss in patients on chronic medications).
Who should care
Read the original on Clinical Oral Implants Research
Full reporting and any paywall content live on onlinelibrary.wiley.com. We summarize and score; we do not republish.
Related
- ·Regulatory
Dental Practices Are Off the Hook for Beneficial Ownership Reporting
- ·Regulatory
American Regent, Inc. Issues Voluntary Nationwide Recall of Three Lots of Epinephrine Injection, USP 30 mg/ 30 mL (1 mg/mL) Due to the Presence of Particulate Matter and Lack of Assurance of Sterility
- ·Regulatory
California dental clinics brace for increased costs ahead of Medicaid cuts
- ·Regulatory
US has nearly 8,000 dental professional shortage areas: HRSA